OncoMatch/Clinical Trials/NCT06440005
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Is NCT06440005 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies AGX101 for cancer.
Treatment: AGX101 — AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population. AGX101will be administered intravenously. Dosing of AGX101 will be repeated once every 3, 6 or 9 weeks. Participants may continue study treatment until disease progression, unacceptable toxicity, or consent withdrawal. Subjects will attend an end of treatment visit and will receive two safety follow-up telephone contacts up to 90 days following the last dose of study drug.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Breast Carcinoma
Prostate Cancer
Colorectal Cancer
Pancreatic Cancer
Hepatocellular Carcinoma
Sarcoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
adequate organ function
Kidney function
adequate organ function
Liver function
adequate organ function
Cardiac function
LVEF 50%, as determined on cardiac ECHO or cardiac multiple-gated acquisition (MUGA) scan
Have adequate organ function; LVEF 50%, as determined on cardiac ECHO or cardiac multiple-gated acquisition (MUGA) scan
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- USC/Norris Comprehensive Cancer Center · Los Angeles, California
- Florida Cancer Specialist · Sarasota, Florida
- Washington University School of Medicine · St Louis, Missouri
- Sarah Cannon Research Center · Nashville, Tennessee
- NEXT Oncology · San Antonio, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify